Perseus Proteomics (TSE:4882) Cyclically Adjusted PS Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4882 Perseus Proteomics Inc TSE:4882
57 GF Score
Price 円145.00
GF Value 円440.54
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Perseus Proteomics Cyclically Adjusted PS Ratio?

Perseus Proteomics does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Perseus Proteomics  (TSE:4882) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Perseus Proteomics Cyclically Adjusted PS Ratio Related Terms


Perseus Proteomics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Perseus Proteomics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perseus Proteomics Cyclically Adjusted PS Ratio Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Perseus Proteomics Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4882 vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Perseus Proteomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perseus Proteomics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Perseus Proteomics's Cyclically Adjusted PS Ratio falls into.


TSE:4882
57GF Score
Perseus Proteomics Inc TSE:4882
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perseus Proteomics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Perseus Proteomics does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is Perseus Proteomics (TSE:4882) Overvalued in 2026?

Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued. The current stock price of 円145.00 is trading 67.1% below its estimated GF Value™ of 円440.54. GuruFocus considers Perseus Proteomics to be Significantly Undervalued.

Key valuation signals for TSE:4882:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: 円440.54 vs. price of 円145.00 (67.1% below fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Perseus Proteomics Business Description

Address 30-1 Hakozakicho, Nihonbashi, Chuo-ku, AiNihombashi EAST 3rd floor, Tokyo, JPN, 103-0015
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
57GF Score

Get the complete analysis for TSE:4882

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円145.00
Price
円440.54
GF Value